Amylyx Pharmaceuticals (AMLX) Competitors

Amylyx Pharmaceuticals logo
$27.80 -2.49 (-8.22%)
Closing price 04:00 PM Eastern
Extended Trading
$27.78 -0.02 (-0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AMLX vs. SMMT, KYMR, BMRN, PCVX, and IBRX

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? Amylyx Pharmaceuticals's main competitors and comparable companies include Summit Therapeutics (SMMT), Kymera Therapeutics (KYMR), BioMarin Pharmaceutical (BMRN), Vaxcyte (PCVX), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Amylyx Pharmaceuticals compare to Summit Therapeutics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Amylyx Pharmaceuticals' return on equity of -41.54% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amylyx PharmaceuticalsN/A -41.54% -38.91%
Summit Therapeutics N/A -138.82%-117.11%

Amylyx Pharmaceuticals currently has a consensus price target of $43.71, suggesting a potential upside of 44.32%. Summit Therapeutics has a consensus price target of $28.61, suggesting a potential upside of 102.17%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Amylyx Pharmaceuticals' score of 0.50 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amylyx Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Amylyx Pharmaceuticals has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.49, indicating that its stock price is 249% less volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 81.8% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amylyx Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amylyx Pharmaceuticals$87.37M44.57-$144.74M-$1.44N/A
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A

Summary

Amylyx Pharmaceuticals beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Kymera Therapeutics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amylyx Pharmaceuticals has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amylyx Pharmaceuticals$87.37M44.57-$144.74M-$1.44N/A
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A

Amylyx Pharmaceuticals has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Amylyx Pharmaceuticals presently has a consensus price target of $43.71, suggesting a potential upside of 44.32%. Kymera Therapeutics has a consensus price target of $139.16, suggesting a potential upside of 9.09%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -22.39% beat Amylyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amylyx PharmaceuticalsN/A -41.54% -38.91%
Kymera Therapeutics -285.33%-22.39%-20.48%

In the previous week, Amylyx Pharmaceuticals had 7 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Amylyx Pharmaceuticals' score of 0.50 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amylyx Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Amylyx Pharmaceuticals beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to BioMarin Pharmaceutical?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

BioMarin Pharmaceutical has higher revenue and earnings than Amylyx Pharmaceuticals. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amylyx Pharmaceuticals$87.37M44.57-$144.74M-$1.44N/A
BioMarin Pharmaceutical$3.22B3.44$348.90M-$0.10N/A

Amylyx Pharmaceuticals has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Amylyx Pharmaceuticals currently has a consensus target price of $43.71, suggesting a potential upside of 44.32%. BioMarin Pharmaceutical has a consensus target price of $87.22, suggesting a potential upside of 52.40%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 9 mentions for BioMarin Pharmaceutical. Amylyx Pharmaceuticals' average media sentiment score of 0.50 beat BioMarin Pharmaceutical's score of 0.35 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amylyx Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioMarin Pharmaceutical
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Amylyx Pharmaceuticals has a net margin of 0.00% compared to BioMarin Pharmaceutical's net margin of -0.52%. BioMarin Pharmaceutical's return on equity of 5.58% beat Amylyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amylyx PharmaceuticalsN/A -41.54% -38.91%
BioMarin Pharmaceutical -0.52%5.58%3.51%

Summary

BioMarin Pharmaceutical beats Amylyx Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Amylyx Pharmaceuticals' return on equity of -41.54% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -42.04% -36.82%
Amylyx Pharmaceuticals N/A -41.54%-38.91%

Vaxcyte has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

Amylyx Pharmaceuticals has higher revenue and earnings than Vaxcyte. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$766.63M-$8.06N/A
Amylyx Pharmaceuticals$87.37M44.57-$144.74M-$1.44N/A

Vaxcyte currently has a consensus price target of $110.50, suggesting a potential upside of 74.37%. Amylyx Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 44.32%. Given Vaxcyte's higher possible upside, equities research analysts clearly believe Vaxcyte is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Amylyx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Vaxcyte had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 12 mentions for Vaxcyte and 11 mentions for Amylyx Pharmaceuticals. Vaxcyte's average media sentiment score of 0.88 beat Amylyx Pharmaceuticals' score of 0.50 indicating that Vaxcyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amylyx Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Vaxcyte beats Amylyx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to ImmunityBio's net margin of -607.79%. ImmunityBio's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-607.79% N/A -54.83%
Amylyx Pharmaceuticals N/A -41.54%-38.91%

ImmunityBio has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 25 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 36 mentions for ImmunityBio and 11 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.50 beat ImmunityBio's score of -0.18 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
3 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)
Neutral
Amylyx Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ImmunityBio presently has a consensus price target of $16.00, suggesting a potential upside of 165.78%. Amylyx Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 44.32%. Given ImmunityBio's higher possible upside, research analysts clearly believe ImmunityBio is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Amylyx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Amylyx Pharmaceuticals has lower revenue, but higher earnings than ImmunityBio. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M56.53-$351.40M-$1.08N/A
Amylyx Pharmaceuticals$87.37M44.57-$144.74M-$1.44N/A

Summary

ImmunityBio beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMLX vs. The Competition

MetricAmylyx PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.84B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5532.9127.39
Price / Sales40.9116.028.595.74
Price / CashN/A26.3721.9322.50
Price / Book4.744.074.403.70
Net Income-$144.74M-$22.86M$3.52B$392.17M
7 Day Performance-7.98%-7.26%-5.34%-4.53%
1 Month Performance5.54%-4.96%-3.61%-5.86%
1 Year Performance119.07%-2.87%0.01%-7.78%

Amylyx Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMLX
Amylyx Pharmaceuticals
3.0281 of 5 stars
$27.80
-8.2%
$43.71
+57.2%
+138.7%$3.84B$87.37MN/A136
SMMT
Summit Therapeutics
2.6441 of 5 stars
$17.84
+9.2%
$28.61
+60.4%
-21.5%$12.93BN/AN/A265
KYMR
Kymera Therapeutics
2.0649 of 5 stars
$138.86
+5.4%
$139.16
+0.2%
+96.4%$11.63B$39.21MN/A285
BMRN
BioMarin Pharmaceutical
4.4302 of 5 stars
$57.18
+2.1%
$87.91
+53.7%
+4.6%$11.07B$3.22B32.103,221
PCVX
Vaxcyte
3.0815 of 5 stars
$67.53
+5.7%
$110.50
+63.6%
+30.1%$9.77BN/AN/A507

Related Companies and Tools


This page (NASDAQ:AMLX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners